Holen Sie sich die Stockscreener-App
51.65
0.87%
-0.468
Schlusskurs vom Vortag:
$52.12
Offen:
$52.34
24-Stunden-Volumen:
536.35K
Relative Volume:
0.21
Marktkapitalisierung:
$9.92B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
19.20
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-3.86%
1M Leistung:
-5.60%
6M Leistung:
-8.13%
1J Leistung:
-21.17%
1-Tages-Spanne:
$51.47
$52.48
1-Wochen-Bereich:
$50.90
$54.33
52-Wochen-Spanne:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
51.66 | 10.01B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.65 | 115.62B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
736.49 | 79.10B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
845.77 | 52.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
390.15 | 51.72B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
201.38 | 42.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Herabstufung | Stifel | Buy → Hold |
| 2025-09-08 | Eingeleitet | H.C. Wainwright | Neutral |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
Update Recap: How BioMarin Pharmaceutical Inc stock performs in weak economyJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Do Options Traders Know Something About BMRN Stock We Don't? - Yahoo Finance
Hudson Bay Capital Management LP Sells 60,425 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP - MarketBeat
Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boone Capital Management LLC Has $24.60 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
AQR Capital Management LLC Acquires 2,654,768 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Camber Capital Management LP Has $32.98 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story - Sahm
Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges - Finviz
Leerink cuts BioMarin Pharmaceutical Inc. (BMRN) price target to $60, citing valuation and competitive challenges - MSN
California Public Employees Retirement System Sells 102,629 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Axa S.A. - MarketBeat
Inozyme Pharma Acquisition Finalized by BioMarin - Ad-hoc-news.de
BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink - Finviz
BioMarin Pharmaceutical Inc. (BMRN) outlook lowered by Leerink - MSN
Diadema Partners LP Has $10.60 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Amundi Sells 4,838,064 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Arrowstreet Capital Limited Partnership Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
August 2026 Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Jump Financial LLC Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Technical Reactions to BMRN Trends in Macro Strategies - news.stocktradersdaily.com
BioMarin Pharmaceutical Inc. (BMRN): A bull case theory - MSN
1832 Asset Management L.P. Acquires Shares of 26,034 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Schroder Investment Management Group Trims Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What margin trends mean for BioMarin Pharmaceutical Inc. stockJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Dodge & Cox - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyJuly 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Finviz
BioMarin Loses Hormone Patent In Europe - Law360
BioMarin Pharmaceutical (NASDAQ:BMRN) Lowered to "Market Perform" Rating by Leerink Partners - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to "Hold" at Leerink Partnrs - MarketBeat
Is BioMarin Pharmaceutical Inc. stock undervalued vs historical averagesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - Newser
Can BioMarin Pharmaceutical Inc. (BM8) stock withstand sector downturns2025 Key Lessons & Technical Pattern Based Signals - Newser
Mackenzie Financial Corp Grows Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
2,043,879 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Norges Bank - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform By Investing.com - Investing.com South Africa
Uber To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
BMRN Experiences Downgrade and Price Target Cut by Leerink Partn - GuruFocus
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Sio Capital Management LLC - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform - Investing.com
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 - marketscreener.com
Hsbc Holdings PLC Boosts Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Korea Investment CORP Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
Edgestream Partners L.P. Has $7.12 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):